# Huagai Capital

> Huagai Capital is a VC fund in Beijing backing Health Care and Biotechnology. See 144 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 144
- Last investment: Jul 2026
- Lead investor: 43%
- Fund size: $430M
- Last fund: Dec 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/华盖资本有限责任公司
- Website: http://www.hgcapital.cn/

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

## Contacts

5 contacts available for Huagai Capital. Shizune tracks 5 team members at Huagai Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/huagai-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Angel | $425k–$15M |
| Series A | $1.4M–$67M |
| Series B | $3.5M–$147M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 38 | 26% |
| Biotechnology | 29 | 20% |
| Medical | 27 | 19% |
| Manufacturing | 17 | 12% |
| Pharmaceutical | 15 | 10% |

130 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 49 | 34% |
| Series B | 27 | 19% |
| Angel | 16 | 11% |
| Seed | 12 | 8% |
| Series C | 10 | 7% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 112 | 78% |
| United States | 6 | 4% |
| Hong Kong | 2 | 1% |
| Germany | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lu Binghui | President & Co-Founder | 0 | https://shizune.co/investors/profile/lu-binghui |
| Meng Nan | Executive General Manager | 1 | https://shizune.co/investors/profile/meng-nan-d449 |
| Wang Shaokun | Vice President | 1 | https://shizune.co/investors/profile/wang-shaokun |
| Xiaolin Xu | Chairman & Co-founder | 3 | https://shizune.co/investors/profile/xiaolin-xu |
| Zeng Zhiqiang | Managing Partner | 4 | https://shizune.co/investors/profile/zeng-zhiqiang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SeaArt | SeaArt is an AI creativity platform that provides tools for generating and editing images, videos, audio, and interactive AI character chats. The service includes text-to-image art generation, text-to-video and image-to-video creation, and an AI chatbot assistant with customizable characters. SeaArt also offers AI audio synthesis with multiplevoices, workflow control through ComfyUI, model training and hosting for Stable Diffusion based models, and swift AI tools for upscaling and filtering media. A built-in community enables sharing, remixing, challenges, and creator incentive programs for monetizing AI-generated works. | $14.7M | Series B | Jul 13, 2026 |  |
| GigaAI | Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space. | $147.9M | Series B | Jun 15, 2026 |  |
| Falcon Technology | Falcon Technology focuses on DSA processor design innovation, developing a dedicated computing technology ecosystem based on the RISC-V architecture to deliver high-performance, energy-efficient processing solutions for next-generation intelligent computing applications. | $14.7M | Angel | May 20, 2026 |  |
| SenseTime | SenseTime Medical is an AI healthcare firm that creates solutions for hospitals, research institutions, and the global medical market. Through its SenseCare platform, the company provides over 40 specialized AI modules and maintains strategic partnerships with organizations like Roche, Midea, and Ruijin Hospital to streamline patient services andmedical innovation. | $73.3M | Series A | Apr 20, 2026 |  |
| PrinoPharma | PrinoPharma focuses on developing novel druggable sites targeting difficult-to-drug or existing druggable targets. | $14.5M | Angel | Mar 10, 2026 |  |
| QL Biopharma | QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases. | $72.8M | Series C | Mar 02, 2026 |  |
| Shanghai Genentech Biotech Co. |  | $28.4M | Private Equity | Dec 16, 2025 |  |
| Synaire | Synaire engaged in the research and development, production and other related businesses of home ventilators, oxygen concentrators, and non-invasive ventilators. |  | Seed | Dec 12, 2025 |  |
| Hyperway Pharm | Hyperway Pharm is a pharmaceutical R&D and production enterprise with R&D as the core driving force. It adheres to the philosophy of “Hai Na Baichuan, Bocai, Changzhi, Good People, and Great Deeds”, and is committed to building a world-leading research and development platform for small molecule innovative drugs and high-end APIs. Researchand development platform for research and development platforms and high-tech barriers. Its core founding team is a special high-end talent in Chengdu, Sichuan Province, and has many Fortune 500 companies such as Bayer, Johnson & Johnson, Sanofi and Merck, as well as “Kingming Kant”. Work experience of domestic well-known pharmaceutical companies such as “Hengrui”, “Yangzijiang”, “Hai Cisco”, “Smart Chemical” and “Bite Pharmaceutical”, with rich experience in international and domestic drug development and management, and led the team. It has successively developed a number of world-class innovative drugs (which have entered clinical trials) and a number of high-end high-end generic drugs | $28.1M | Series B | Oct 22, 2025 |  |
| Moyang Biotechnology | Moyang Biotechnology specializes in the development and consulting services of medical biomaterials for beauty sector. |  | Series C | Aug 08, 2025 |  |

10 of 144 investments shown.

## Co-investors
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 6 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 6 deals together
- [Baidu Ventures](https://shizune.co/investors/profile/baidu-ventures) — VC Fund, 5 deals together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 5 deals together
- [Dyee Capital](https://shizune.co/investors/profile/dyee-capital) — VC Fund, 5 deals together
- [Green Pine Capital Partners](https://shizune.co/investors/profile/green-pine-capital-partners) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care Investors in Asia](https://shizune.co/investors/health-care-investors-asia)
- [Health Care VC Funds in Asia](https://shizune.co/investors/health-care-vc-funds-asia)
- [Health Care Investors in China](https://shizune.co/investors/health-care-investors-china)
- [Health Care VC Funds in China](https://shizune.co/investors/health-care-vc-funds-china)
- [Medical Investors in China](https://shizune.co/investors/medical-investors-china)
- [Medical Investors in Asia](https://shizune.co/investors/medical-investors-asia)

## FAQ

### What does Huagai Capital invest in?

Huagai Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 144 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Huagai Capital's check size?

Huagai Capital typically joins rounds of $425k–$15M at Angel, $1.4M–$67M at Series A and $3.5M–$147M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Huagai Capital participates in.

### How do I contact Huagai Capital?

Public channels for Huagai Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Huagai Capital?

The team at Huagai Capital includes Lu Binghui (President & Co-Founder), Meng Nan (Executive General Manager) and Wang Shaokun (Vice President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co